Ozempic®, Wegovy®, and GLP-1 Medications Explained: What’s the Difference?

Ozempic. Wegovy. Mounjaro®. Zepbound®. Semaglutide. Tirzepatide. Rybelsus®. And now oral Wegovy and Foundayo®.

If these names have blurred into a single undifferentiated category in your mind, that is a completely reasonable response to how they are discussed. “Ozempic” in particular has become a generic shorthand for the entire class, which is why people ask their provider for Ozempic when the medication appropriate for their situation may be something else entirely.

The distinctions become clearer when you sort medications by active ingredient, formulation, and FDA-approved indication. Those differences matter for dosing, safety, insurance coverage, and how to interpret clinical-trial results. Choosing the right medication for an individual patient is a clinical decision.

Here is the map.

Start With Two Molecules

Almost everything in this conversation comes down to two active ingredients.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut naturally releases after eating, which signals fullness to the brain, slows gastric emptying, and stimulates insulin release when blood glucose is elevated.

Tirzepatide is a dual agonist. It activates the GLP-1 receptor and the GIP receptor — glucose-dependent insulinotropic polypeptide, a second gut hormone involved in metabolic regulation. Acting on two receptors rather than one appears to produce greater weight loss on average.

Everything below is one of these two molecules, or — as of 2026 — a newer third option.

The Brand Names, Sorted

The single most useful thing to understand is that the same molecule is sold under different brand names depending on what it is approved to treat, and that determines coverage.

BrandMoleculeApproved primarily forRoute
OzempicSemaglutideType 2 diabetesWeekly injection
WegovySemaglutideWeight management, cardiovascular risk reduction, MASHWeekly injection or daily tablet
RybelsusSemaglutideType 2 diabetesDaily tablet
MounjaroTirzepatideType 2 diabetesWeekly injection
ZepboundTirzepatideWeight management, obstructive sleep apneaWeekly injection
FoundayoOrforglipronWeight managementDaily tablet

So are Ozempic and Wegovy the same drug? Chemically, yes — both are semaglutide. But they are approved for different conditions and dosed differently. Ozempic’s maintenance dosing for type 2 diabetes runs up to 2 mg weekly; Wegovy’s standard weight-management maintenance dose is 2.4 mg weekly, and a higher-dose injectable formulation was approved in March 2026. Prescribing Ozempic purely for weight loss in a patient without diabetes is off-label use, and insurers generally deny it on that basis. Wegovy is the on-label choice for weight management.

Mounjaro and Zepbound are the same relationship: identical molecule, tirzepatide, split by indication. Mounjaro for type 2 diabetes, Zepbound for weight management and for obstructive sleep apnea in adults with obesity.

What the Trials Actually Show

The pivotal trials below provide useful context, but they report group averages in defined study populations. They do not predict an individual patient’s result.

Semaglutide 2.4 mg — STEP 1. In a 68-week randomized trial of 1,961 adults, semaglutide produced a mean weight reduction of 14.9% versus 2.4% on placebo. Among participants receiving semaglutide, 86.4% lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%.

Tirzepatide — SURMOUNT-1. In a 72-week trial of 2,539 adults with obesity or overweight without diabetes, mean weight reduction was 20.9% at the 15 mg dose, 19.5% at 10 mg, and 15.0% at 5 mg.

Head-to-head – SURMOUNT-5. In a 72-week randomized trial of 751 adults with obesity and no diabetes, tirzepatide produced a mean weight reduction of 20.2% versus 13.7% with semaglutide. Mean waist-circumference reduction was 18.4 cm versus 13.0 cm. Gastrointestinal adverse events were common with both agents; gastrointestinal events led to treatment discontinuation in 2.7% of tirzepatide participants and 5.6% of semaglutide participants.

Subgroup results can be interesting, but they should not be used to predict how a particular person will respond. The most reliable comparison is the trial’s overall randomized result.

Does that make tirzepatide the better medication? In SURMOUNT-5, it produced greater average weight reduction in the population studied. That does not make it the best choice for every patient. Treatment selection also depends on medical history, labeled indications, side-effect tolerance, access, cost, and patient preference.

The Newest Options: Two Pills, Two Different Drugs

This is where most current coverage gets confused, so it is worth being precise.

Oral Wegovy – semaglutide, 25 mg once daily. FDA approved it on December 22, 2025 for chronic weight management and cardiovascular risk reduction in the labeled populations. In the OASIS 4 trial, mean weight reduction at 64 weeks was 13.6% with oral semaglutide versus 2.2% with placebo. That result should not be treated as a head-to-head comparison with injectable semaglutide or tirzepatide, because the trials differed in design and populations.

The administration requirements are specific: oral semaglutide is taken in the morning on an empty stomach with no more than four ounces of plain water, followed by at least a 30-minute wait before food, beverages, or other oral medications. Patients should follow the current prescribing instructions provided with their medication.

Foundayo — orforglipron, daily tablet. FDA approved on April 1, 2026 for chronic weight management in adults with obesity, or overweight with a weight-related condition. This is not semaglutide. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist — a structurally different kind of drug, made by Eli Lilly rather than Novo Nordisk.

A practical difference is that orforglipron is a small molecule rather than a peptide. Under its FDA labeling, it can be taken without the same fasting and water restrictions used for oral semaglutide, which may matter for adherence and preference.

In its pivotal trial, mean weight reduction varied by dose, ranging from 7.4% to 11.1% at 72 weeks. Those results are clinically meaningful, but cross-trial comparisons with semaglutide or tirzepatide should be made cautiously because the studies were not head-to-head.

Oral and injectable treatments therefore involve different trade-offs in route, dosing routine, evidence, side effects, cost, and access. A licensed clinician can help interpret those trade-offs for an individual patient.

Compounded GLP-1 Medications: What Changed After the Shortages

The regulatory landscape for compounded semaglutide and tirzepatide changed substantially after the FDA determined that the shortages had been resolved.

During the shortages, federal law allowed certain pharmacies and outsourcing facilities to compound copies of semaglutide or tirzepatide under shortage-related provisions. Once a shortage ends, those broad shortage-based pathways narrow and the rules governing products that are essentially copies of commercially available drugs again become central.

FDA declared the tirzepatide shortage resolved in 2024 and the semaglutide shortage resolved on February 21, 2025, followed by temporary enforcement-discretion periods that have since ended. As a result, compounders generally cannot rely on the former shortage exception to make routine copies of these commercially available drugs.

Patient-specific compounding can still be permitted in limited circumstances when applicable federal and state requirements are satisfied. For traditional 503A pharmacies, for example, federal law restricts regular or inordinate compounding of products that are essentially copies of commercially available drugs, while allowing a prescriber-documented change that produces a significant difference for an identified patient. The legal analysis depends on the facts, the compounder, and the prescription; it should not be reduced to a blanket statement that all compounded semaglutide or tirzepatide is either legal or illegal.

FDA has also reported safety and quality concerns involving unapproved compounded GLP-1 products. As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. These reports do not by themselves prove causation and may be incomplete, but FDA has separately documented dosing errors, quality concerns, and misleading marketing practices.

  • Dosing errors. FDA has described serious adverse events when patients or clinicians measured or calculated doses incorrectly, particularly when compounded products were supplied in multi-dose vials rather than fixed-dose pens.
  • Active-ingredient concerns. FDA has warned about products made with semaglutide sodium or semaglutide acetate, salt forms that are different from the active ingredient in FDA-approved semaglutide products.
  • Shipping and storage concerns. FDA has received complaints about compounded injectable GLP-1 products arriving warm or inadequately refrigerated.
  • Fraudulent or misleading labeling. FDA has warned about products that misstate the source pharmacy or obscure who compounded the medication.
  • Unapproved investigational ingredients. FDA has specifically warned consumers about products sold as retatrutide or cagrilintide outside clinical trials; these ingredients are not FDA-approved drugs and are not eligible to be marketed as approved therapies.

FDA has also warned telehealth marketers not to imply that a compounded GLP-1 is the same as, generic for, or FDA-approved like a branded product, and not to obscure the identity of the pharmacy that compounded it. A compounded product should be described as compounded, with its regulatory status made clear.

If a compounded medication is being considered, useful questions include: Why is a compounded product appropriate for my individual situation? Which state-licensed pharmacy will prepare it? What active ingredient and concentration will I receive? How will dosing be measured? How does its compounded status differ from an FDA-approved product? The prescribing clinician should be able to explain the rationale, risks, alternatives, and monitoring plan.

Which One Is Right for You?

The right option, if any, depends on factors an article cannot assess: the indication being treated, BMI and weight-related conditions, diabetes and cardiovascular history, sleep apnea, pregnancy status, other medications, gastrointestinal and gallbladder history, kidney function, contraindications in the specific product label, cost, and route preference.

The useful takeaway is not that one medication is universally best. It is that products with similar-sounding names can differ in active ingredient, indication, dosing, evidence, and regulatory status, and those differences matter when a clinician and patient make a treatment decision.

Vantage Telehealth is a technology platform that connects patients with independent licensed clinicians through Impact Health USA. Those clinicians determine whether treatment is appropriate and make all prescribing decisions. Medication availability through Vantage may differ from the products discussed in this educational article and can change over time. Vantage does not manufacture or dispense medications, and compounded medications are not FDA-approved or evaluated by FDA for safety, effectiveness, or quality.

Learn more about GLP-1 weight loss at Vantage

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, but they are FDA-approved for different uses and have different dosing and formulations. Ozempic is approved for type 2 diabetes and certain cardiovascular and kidney-related risk-reduction indications in labeled populations. Wegovy is approved for chronic weight management and certain additional indications, including cardiovascular risk reduction, with injectable and oral formulations now available. Coverage varies by plan and indication, so FDA approval does not guarantee insurance coverage.

Are Ozempic, Wegovy, and semaglutide all the same drug?

They all contain semaglutide as the active ingredient. Semaglutide is the generic molecule name; Ozempic, Wegovy, and Rybelsus are brand names for it, each approved for different indications and available in different formulations. Ozempic and Wegovy are injections; Rybelsus is a daily tablet for type 2 diabetes, and Wegovy is now also available as a 25 mg daily tablet for weight management. Same molecule, different approvals and dosing.

How does Mounjaro (tirzepatide) compare to Wegovy (semaglutide) for weight loss?

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide acts at the GLP-1 receptor. In SURMOUNT-5, tirzepatide produced greater average weight reduction than semaglutide over 72 weeks in adults with obesity who did not have diabetes. Mounjaro is the tirzepatide brand approved for type 2 diabetes; Zepbound is the brand approved for chronic weight management and certain other labeled uses. Trial averages do not predict an individual response.

What is compounded semaglutide and how does it compare to brand-name GLP-1s?

Compounded semaglutide is prepared by a compounding pharmacy rather than manufactured as an FDA-approved product. The semaglutide shortage was resolved in February 2025, so compounders can no longer rely on the broad shortage exception to make routine copies. Patient-specific compounding may still be permitted when applicable legal requirements are met. Compounded drugs are not FDA-approved or evaluated by FDA for safety, effectiveness, or quality, and FDA has reported dosing, ingredient, shipping, and labeling concerns with some compounded GLP-1 products.

Which GLP-1 medication produces the most weight loss on average?

Across separate pivotal trials, tirzepatide has produced larger average weight reductions than semaglutide, and SURMOUNT-5 confirmed a larger mean reduction with tirzepatide in a direct comparison. That does not identify the best medication for a particular patient. Indication, medical history, contraindications, side effects, access, cost, and route all matter.

Is there an oral GLP-1 pill available for weight loss?

Yes. Oral Wegovy contains semaglutide and was FDA-approved for chronic weight management in December 2025; its label includes specific fasting and water instructions. Foundayo contains orforglipron, a different small-molecule GLP-1 receptor agonist approved in April 2026, and it does not use the same fasting protocol. Their trial results come from separate studies and should not be treated as a head-to-head comparison.

Selected References

Clinical claims are supported primarily by peer-reviewed literature; FDA sources are used for labeling, approval, and compounding-regulatory facts.

• STEP 1 – Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM, 2021)

• SURMOUNT-1 – Tirzepatide Once Weekly for the Treatment of Obesity (NEJM, 2022)

• SURMOUNT-5 – Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (NEJM, 2025)

• OASIS 4 – Oral Semaglutide 25 mg in Adults with Overweight or Obesity (NEJM, 2025)

• ATTAIN-1 – Orforglipron for Obesity Treatment (NEJM, 2025)

• FDA – Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

See how Vantage Telehealth can help — Get Started →

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, treatment, or an individualized recommendation. Clinical-trial results are group averages and do not predict individual outcomes. Vantage Telehealth is a technology platform and is not a medical services provider. Medical services are provided by independent licensed clinicians through Impact Health USA, and all prescribing decisions are made solely by the treating clinician. Vantage does not manufacture or dispense medications. Compounded drug products are not FDA-approved or evaluated by FDA for safety, effectiveness, or quality. Mention of an FDA-approved brand does not mean that product is available through Vantage. Drug approvals, labeling, availability, and compounding rules can change; information should be re-verified before publication and before relying on it. Never start, stop, change, or obtain a prescription medication without guidance from a qualified licensed clinician.

Trademark notice: Ozempic®, Wegovy®, Rybelsus® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound®, Foundayo® are registered trademarks of Eli Lilly and Company. Vantage Telehealth is not affiliated with, endorsed by, or sponsored by these companies. Brand names are used only to identify the medications discussed.